NYU Dataset

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia

UID: 10111
* Corresponding Author
Description
Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains. Varenicline is a partial nicotinic agonist which is effects as an anti-smoking drug in cigarette smokers, although concerns have been raised about potential psychiatric side-effects. This data is from a double-blind placebo controlled study in 87 schizophrenic smokers to evaluate the effect of varenicline on measures of smoking, cognition, psychiatric symptoms, and side-effects in schizophrenic patients who are cigarette smokers.
Timeframe
2012
Subject of Study
Subject Domain
Population Age
Adult (19 years - 64 years)
Subject Gender
Male
Female
Keywords

Access

Restrictions
Free to All
Instructions
Data and associated documentation are available on the figshare repository.
Access via figshare

Data and Protocol

Associated Publications
Data Type
Study Type
Interventional
Dataset Format(s)
SPSS
Other Resources
ClinicalTrials.gov

NCT00802919